Results 201 to 209 of about 25,087 (209)

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Lancet Oncology, The, 2020
Shaji K Kumar, Simon J Harrison, Michele Cavo   +2 more
exaly  

Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma

Nature Medicine, 2018
Rishu Agarwal, Yih-Chih Chan, Constantine S Tam   +2 more
exaly  

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

Journal of Clinical Oncology, 2019
Andrew H Wei, Walter Fiedler, Tara L Lin
exaly  

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

Lancet Oncology, The, 2016
Stephan Stilgenbauer, Johannes Schetelig, Steven Coutre   +2 more
exaly  

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

Journal of Clinical Oncology, 2019
Arnon P Kater, John F Seymour, Peter Hillmen   +2 more
exaly  

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

Journal of Clinical Oncology, 2019
Peter Hillmen, Chris Fegan, Anna Schuh
exaly  

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

Lancet Oncology, The, 2017
John F Seymour, Danielle M Brander, Jacqueline Barrientos   +2 more
exaly  

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2016
Andrew W Roberts, Matthew S Davids, John M Pagel   +2 more
exaly  

Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response

Science Translational Medicine, 2019
David Sharon, Sara Mirali, Justin M Di Trani   +2 more
exaly